CNS target could lead to development of drugs for diabetes
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
List view / Grid view
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
Researchers have suggested that dormant HIV can be eradicated from cells by attacking it based on its viral activities.
A study using stem cells has revealed that DCM-causing mutations in LMNA disrupt the organisation of DNA in the nucleus of heart muscle cells.
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
Researchers have found a druggable insulin inhibitory receptor named inceptor that could provide a drug target for diabetes.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
Researchers have discovered that giving L-tyrosine and PCS to mice prevents lung inflammation and an allergic asthma response.
Scientists have found that a new knee injection using nanomedicine could prevent the effects of osteoarthritis.
Researchers have isolated a compound from I. viscosa that kills the "brain-eating" amoebae from primary amoebic meningoencephalitis (PAM).
Tests in Alzheimer's disease mouse models have shown that hydrogen sulphide can improve cognitive and motor function by 50 percent.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Researchers have found that spermidine can ramp up autophagy and boost T-cell function, potentially increasing the protective effects of vaccines in older adults.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.